Angle Files De Novo Submission For Parsortix System In Breast Cancer

The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.

Cancer cells on scientific background.3d illustration

UK liquid biopsy company ANGLE plc has filed a de novo submission with the US Food & Drug Administration for its Parsortix system to capture metastatic breast tumor cells

The system is designed to harvest circulating tumor cells (CTC's) from a patient’s blood sample with a microfluidic cassette . As the blood flows through the system, the cancer cells...

More from Oncology

More from Device Area